Last reviewed · How we verify
Quetiapin
At a glance
| Generic name | Quetiapin |
|---|---|
| Sponsor | Sykehuset Innlandet HF |
| Target | Aldehyde oxidase, 5-hydroxytryptamine receptor 1E, 5-hydroxytryptamine receptor 5A |
| Modality | Small molecule |
| Therapeutic area | Neuroscience |
| Phase | FDA-approved |
Approved indications
- Bipolar affective disorder, current episode depression
- Bipolar affective disorder, current episode manic
- Bipolar disorder
- Bipolar disorder in remission
- Depression Treatment Adjunct
- Schizophrenia
Common side effects
- Somnolence
- Dizziness
- Dry mouth
- Constipation
- ALT increased
- Weight gain
- Dyspepsia
Serious adverse events
- Hypotension
- Somnolence (leading to discontinuation)
Key clinical trials
- Efficacy and Safety of Quetiapine Versus Quetiapine Plus Lithium in Bipolar Depression (PHASE3)
- FAST-A Study to Evaluate the Efficacy and Safety of Quetiapin IR in Patients With Acute Psychosis (PHASE3)
- Discontinuation of Antipsychotics and Antidepressants Among Patients With BPSD (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |